RVL Pharmaceuticals plc

Good day and thank you for standing by. Welcome to the RVL Pharmaceuticals fourth quarter 2021 earnings results and business update call. At this time, all participants are on a listen-only mode. After the speaker presentation, there will be a question and answer session. Just a question during the session, you need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to speaking today, Lisa Wilson, Investor Relations for RVL. Please go ahead.

Thank you, Operator. Welcome to RVL Pharmaceuticals' fourth quarter 2021 business update call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison, Chief Operating Officer, J.D. Schaub, and Chief Financial Officer, Andy Einhorn. This afternoon, the company issued a press release detailing financial results for the three months ended December 31, 2021. This press release and a webcast of this call can be accessed through the investor section of the RVL website at rvl.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent are regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to RVL's management as of today and involve risks and uncertainties, including those noted in this afternoon's press release and are filing through the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. During this call, we refer to non-GAAP measures such as adjusted EBITDA. For reconciliation of adjusted EBITDA to net income or loss, please see the tables at the end of our press release. The archived webcast of this call will be available for 30 days on our website, rvl.com. For the benefit of those who may be listening to the replay or archived webcast, This call was held and recorded on March 30, 2022. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filing. And with that, I'll turn the call over to RVL CEO, Brian Markison.

Brian Markison Thanks, Lisa, and good afternoon, and thank you for joining our call. While 2021 is in the rearview mirror I believe it is important to look back at a few major milestones. First, we completely reshaped our company from a mixed, branded, and generic specialty pharma company to a growth story focused in ocular medicine and periocular rejuvenation. Our flagship product of NEEQ, indicated for the treatment of acquired ptosis or droopy eyelid, was introduced during the height of the pandemic and throughout last year our eye care team has built a market for a new treatment that can improve vision and lift one's eyelids. Beyond surgery, there was no effective treatment for ptosis, and it was rarely discussed between the patient and provider due to the fact that there was no solution. With the introduction of UpNIC, that situation has changed. Over the last year, we have established safety and efficacy and we have grown the brand every month and every quarter. Now, we are poised to embrace the aesthetic market. We launched in February with a team of 50 experienced territory business managers, and we're off to a great start. If you've seen the headlines in our press release, we expect first quarter sales to range between $5.5 to $6 million, which is a meaningful step up from our fourth quarter last year. We are also reaffirming our guidance for the fourth quarter of this year, which we previously stated would be between $20 and $25 million. It is also noteworthy to mention our expanding relationship with Santan as they take on more territory beyond the major markets that are already under our license agreement and have bought out the approval milestones for Japan, China, and the EU. They have been a terrific partner and are obviously fully committed to developing the brand. Now, I'd like to turn the call over to Andy, who will cover our financial results in greater detail. Andrew?